Incepta launches Pfizer’s anti-Covid pill

Incepta, one of the leading pharmaceutical companies in the country, has announced the launching of Pfizer’s oral antiviral medication – Paxlovid – for the treatment of Covid-19.

Incepta Pharmaceuticals Limited will market the drug under the brand name of Jupitavir.

The Directorate General of Drug Administration granted emergency use authorisation for the drug to treat mild-to-moderate Covid-19 patients, including adults and children of 12 years and above.

Earlier on 22 December 2021, the US Food and Drug Administration granted emergency use authorisation to the drug as the first approved oral therapy for Covid-19 treatment.

This novel antiviral pill showed almost 90 per cent efficacy in preventing hospitalisations and deaths in high-risk patients, and recent lab data suggests that the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.

The drug is co-packaged with Nirmatrelvir and Ritonavir tablets.

The treatment is given as two tablets of Nirmatrelvir and one tablet of Ritonavir together twice a day for five days.

Jupitavir is available by prescription only and should be initiated as soon as possible after diagnosis of Covid-19 and within five days of symptom onset. — New Age